Department of Animal Science, Iowa State University, College of Agriculture and Life Sciences, Ames, IA 50011, USA.
J Anim Sci. 2021 Jun 1;99(6). doi: 10.1093/jas/skab111.
To assess the relative bioavailability of bis-glycinate bound Cu, 90 Angus-cross steers (265 ± 21 kg) were blocked by body weight (BW) to pens with GrowSafe bunks and randomly assigned to dietary treatments (14 to 18 steers/treatment): 0 mg supplemental Cu/kg dry matter (DM; CON), 5 or 10 mg supplemental Cu/kg DM as Cu sulfate (CS5; CS10) or bis-glycinate bound Cu (GLY5; GLY10). Steers received a high antagonist growing diet (analyzed 4.9 mg Cu/kg DM, 0.48% S, and 5.3 mg Mo/kg DM). Steers were weighed at the beginning (days 1 and 0) and end (days 125 and 126) of the trial to determine average daily gain (ADG) and gain:feed (G:F). Blood was collected from all steers on days 0, 28, 56, 84, and 126. Liver samples were collected on days -3 or -2 and day 123 or 124. Data were analyzed using ProcMixed of SAS (experimental unit = steer; fixed effect = treatment and block). Plasma Cu was analyzed as repeated measures (repeated effect = day). Plasma and liver Cu concentrations were regressed against total Cu intake using ProcGLM to calculate relative bioavailability of GLY. Final BW and overall ADG were greatest for CS5 and CS10 and least for CON and GLY5 (P = 0.01). Overall, DMI was not affected by treatment (P = 0.14), but overall G:F tended to be greatest for CS5, CS10, and GLY5 and least for CON (P = 0.08). Total and supplemental Cu intake was greatest for steers supplemented either source at 10 mg Cu/kg DM and least for CON (P < 0.01). However, total and supplemental Cu intake was greater for CS5 than GLY5 (P < 0.01). Final liver Cu concentrations were greatest for CS10, least for CON, CS5, and CS10, and intermediate for GLY10 (P < 0.01). Final plasma Cu was greatest for steers supplemented either source at 10 mg Cu/kg DM (P < 0.01). Relative bioavailability of GLY was 82% compared to CS based on liver Cu (P < 0.01) but did not differ based on plasma Cu (P = 0.60). The lesser bioavailability of GLY relative to CS could be due to a high concentration of dietary antagonists and lower solubility of GLY (68.9% relative to CS) in pH conditions (5.2) similar to the ruminal pH of a beef animal consuming a high concentrate diet. Future studies should examine the effects of bis-glycinate bound Cu fed in blended combination with inorganic Cu sulfate to determine the most effective blend of sources for feedlot cattle experiencing varying amounts of dietary Cu antagonists.
为了评估双甘氨酸结合态铜的相对生物利用度,90 头安格斯杂交公牛(265±21kg)按体重(BW)分为栏,每个栏有 GrowSafe 铺床,并随机分配到以下饲料处理(14 到 18 头牛/处理):0mg 补充铜/千克干物质(DM;CON)、5 或 10mg 补充铜/千克 DM 作为硫酸铜(CS5;CS10)或双甘氨酸结合态铜(GLY5;GLY10)。牛接受高拮抗剂生长日粮(分析铜含量为 4.9mg/kg DM,硫含量为 0.48%,钼含量为 5.3mg/kg DM)。试验开始时(第 1 天和第 0 天)和结束时(第 125 天和第 126 天)对所有牛进行称重,以确定平均日增重(ADG)和增重:饲料(G:F)。所有牛在第 0、28、56、84 和 126 天采集血液。在第-3 天或-2 天和第 123 天或 124 天采集肝脏样本。使用 SAS 的 ProcMixed 分析数据(实验单位=牛;固定效应=处理和块)。血浆铜作为重复测量(重复效应=天)进行分析。使用 ProcGLM 计算 GLY 的相对生物利用度,将血浆和肝脏铜浓度与总铜摄入量进行回归。CS5 和 CS10 的最终体重和总体 ADG 最大,CON 和 GLY5 最小(P=0.01)。总体而言,处理对 DMI 没有影响(P=0.14),但 CS5、CS10 和 GLY5 的总体 G:F 倾向最大,CON 的最小(P=0.08)。CS5 和 GLY5 补充 10mg/kg DM 时总铜和补充铜的摄入量最大,CON 的最小(P<0.01)。然而,CS5 的总铜和补充铜摄入量大于 GLY5(P<0.01)。CS10 的最终肝脏铜浓度最大,CON、CS5 和 CS10 的最低,GLY10 的中间(P<0.01)。CS5 和 GLY5 补充 10mg/kg DM 时最终血浆铜最高(P<0.01)。基于肝脏铜,GLY 的相对生物利用度为 82%,与 CS 相比(P<0.01),但基于血浆铜则没有差异(P=0.60)。GLY 的生物利用度相对 CS 较低,可能是由于高浓度的日粮拮抗剂和 GLY(与 CS 相比为 68.9%)在类似牛采食高浓度日粮时瘤胃 pH(5.2)条件下的低溶解度。未来的研究应研究双甘氨酸结合态铜与无机硫酸铜混合喂养对饲料牛的影响,以确定在遇到不同量日粮铜拮抗剂时最有效的混合来源。